Related Experiment Video
Updated: Apr 12, 2026
06:24
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
1.8K
A Delphi Study to Identify Priority Indicators for Formulary Selection of Innovative Anticancer Drugs in China
Jie Zhao1, Youhong Hu1, Yumei Zhu2
1Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Summary
A new framework helps prioritize cancer drugs in China, balancing patient needs and costs. This consensus-based approach ensures equitable access to innovative treatments while maintaining financial sustainability for hospitals.
Area of Science:
- Health Policy and Management
- Pharmacoeconomics
- Oncology Drug Evaluation
Background:
- Prioritizing innovative anticancer drugs in Chinese hospital formularies requires balancing clinical value, patient access, and financial sustainability.
- Existing methods often lack a multi-stakeholder consensus, leading to potential subjectivity in decision-making.
Purpose of the Study:
- To develop a consensus-based decision support framework for prioritizing innovative anticancer drugs in Chinese hospital formularies.
- The framework aims to integrate clinical benefit, patient access, and financial sustainability.
Main Methods:
- A two-round Delphi survey was conducted with a multidisciplinary expert panel (n=62, n=51) including clinicians, pharmacists, administrators, and patient representatives.
- An initial set of 19 indicators was refined based on expert feedback, with consensus defined as ≥80% agreement on a 5-point Likert scale.
Main Results:
- A structured framework with seven dimensions and 16 indicators was established through consensus.
- Top prioritized dimensions included clinical benefits, safety, and economic impact.
- The framework incorporates China-specific indicators like pharmaceutical access and genetic testing access barriers.
Conclusions:
- The developed framework offers a transparent, standardized, and actionable approach for formulary selection of innovative anticancer drugs in China.
- It reduces subjectivity in value assessment by incorporating diverse stakeholder perspectives and clear criteria.
- The framework provides practical guidance for hospital committees, promoting equitable, evidence-informed, and financially sustainable drug policies.
